Navigation Links
Why women should eat less, move more and consider wearing transdermal HRT patches during menopause
Date:11/24/2008

er thing, when physical activity levels drop and your energy needs are less, it's really important to stay in tune with your hunger signals because you just don't need to eat as much in order to feel satisfied."

There was a related discussion about hormone replacement therapy (HRT) at the conference. Garvan's Professor Lesley Campbell, also Director of the St. Vincent's Diabetes Centre, was an invited speaker at the conference and put forward her view that HRT can actually help protect women against harmful abdominal fat gain and the development of heart disease and Type 2 diabetes.

"During menopause, most women experience redistribution of fat, often gaining weight around the middle," said Professor Campbell. "As we have demonstrated in our research, abdominal fat is a risk factor in the development of cardio-metabolic diseases, such as diabetes. Prior to menopause, women have a lower risk of heart disease than men. Menopause equalises that risk. Women taking HRT appear to maintain their pre-menopausal risk levels."

"It's also worth mentioning that around 10 years ago, Garvan endocrinologists made a very significant breakthrough discovery that is known by surprisingly few women and GPs. They found that taking HRT by wearing transdermal patches - so bypassing the liver may be better for women than taking HRT orally. "

So the overall take home message for women in menopause is eat less, move more and if you're on HRT, consider transdermal patches.


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-434-071-326
Research Australia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. YWCA Survey Reveals Womens Priorities for New Obama Administration
2. Latin Women More Likely to Be Unhappy With Breast Cancer Treatment Decisions
3. 17th Annual Congress on Womens Health Convenes March 27-29, 2009 in Williamsburg, VA
4. Estrogen May Explain Why Women With Cystic Fibrosis Suffer More
5. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
6. Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery
7. Bowel Prep Harder on Women Than Men
8. In a Down Economy, Womens Health Company Announces Growth
9. Lipoprotein Levels May Predict Womens Hypertension Risk
10. Past gains in reducing risk of heart disease have flattened, women especially affected
11. WomenHeart Urges Women to Talk With Doctors About New Study Showing Statins Prevent Heart Attacks, Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 Healthcare Trust of America, Inc. ("HTA"), ... execution of a purchase and sale agreement to acquire ... Angelo, Texas, Corsicana, Texas, and Fort Wayne, Indiana for ... subject to the satisfaction of a number of conditions. ...
(Date:12/4/2009)... Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... AGN ) as its February 2010 "Stock to Study" and ... as its February 2010 "Undervalued Stock" for investors, informational and ... opportunities involving its flagship drug Botox and other products as ...
(Date:12/4/2009)... 4 While Congress debates whether health care ... members point to 45 hospitals that lead through ... the nation while attaining the highest levels of ... hospitals have been named 2009 Leapfrog Top Hospitals, ...
(Date:12/4/2009)... recurrence is a risk for some pediatric cancers, particularly ... according to a new study published online December 4 ... . , This study was undertaken because there is ... up to 20 years) for pediatric cancer patients. , ...
(Date:12/4/2009)... Working with mice, scientists at Johns Hopkins publishing in the ... protein made by a gene called "Twist" may be the ... drive aggressive, metastatic breast cancer from other breast cancer cells. ... a relatively rare subgroup of stem cells in breast tumors ...
Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
... 31 HearAtLast Inc. (Pink,Sheets: HRAL) announced today that ... AXP ) and Wal-Mart Stores (NYSE: WMT ... a special American Express Giftcard,promotion. Starting November 15, 2007, ... they purchase a hearing aid with,their American Express card. ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... therapeutics for,the treatment of cancer, today announced that Paul ... at the 2007 Acumen BioFin Rodman &,Renshaw Conference in ... at 8:50 a.m. (Eastern) on,Tuesday, November 6, 2007. There ...
... ... Margins Exceed 70 Percent, IRVINE, Calif., Oct. 31 ... focused on the,development of minimally invasive technologies for tissue and ... increased gross margins resulted in a reduction,in operating loss in ...
... Switzerland, Oct. 31 Ipsen,(Euronext: FR0010259150; IPN) ... development specialist in oncology and,serious medical conditions ... Ipsen exclusively in-licenses know-how and new patent,applications ... in the world excluding North America, and ...
... WOODCLIFF LAKE, N.J., Oct. 30 Barr,Pharmaceuticals, Inc. ... subsidiary, Barr,Laboratories, Inc., has received tentative approval from ... generic version of Boehringer Ingelheim,Pharmaceuticals, Inc.,s Mirapex(R) (Pramipexole ... Company believes that it is the,first to file ...
... DIEGO, Oct. 30 BioMed Realty Trust, Inc.,(NYSE: ... its third quarter,ended September 30, 2007 after the market ... President and Chief Executive Officer, and Kent Griffin,Chief Financial ... Pacific Time on Thursday, November 8, 2007 to discuss ...
Other Medicine News:Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 2Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 3Health News:HearAtLast Teams Up with American Express and Wal-Mart to Conquer Hearing Loss 4Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 2Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 3Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 4Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 5Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 6Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 7Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 8Health News:Endocare Reports 2007 Third Quarter and Nine-Month Results 9Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 2Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 3Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 4Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 5Health News:Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories 6Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 2Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 3Health News:Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg 4Health News:BioMed Realty Trust to Report 2007 Third Quarter Results 2
(Date:12/4/2009)... 4 Axsun Technologies, Inc., a wholly-owned subsidiary of ... initial development and successful testing of a novel integrated ... this proprietary optical engine design raises the bar on ... for swept source OCT light sources. This approach ...
(Date:12/4/2009)... N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed ... Food and Drug Administration seeking approval to market its ... patent owned by Takeda Pharmaceutical Company Limited. Watson,s ...
(Date:12/4/2009)... BETHESDA, Md., Dec. 4 Drs. Neal Shore and ... recurrence from the additional analysis of secondary end points ... study of FIRMAGON® (monthly degarelix for injection) or monthly ... of treatment. Prostate cancer patients who received FIRMAGON ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 1NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 2NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 3NeoStem Inc Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 50735 4Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 1Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 2Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 3Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare States Frost 26 Sullivan 50733 4New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 4683 1New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 4683 2
... a fully automated, upgradeable platform that ... analyzer along with a customer care ... to focus on patient care. ... are essential to efficient blood gas ...
... Agitators feature sturdy, one-piece ... texture coating and provide ... your platelets. Helmer agitators ... used in Helmer incubators ...
... platelet agitators offer a wide range of ... the drawer storage platform to agitate smoothly, ... wear down and squeak. Sturdy, one-piece perforated ... air circulation for your platelets., ,i.Series platelet ...
Platelet agitator....
Medicine Products: